NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options. Globally, breast cancer contin ...

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks. Adoptive cell therapy b ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. “We’re thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-sa ...

公司业务及研发进展 - 公司专注于基因编辑技术开发免疫肿瘤和遗传性疾病的细胞治疗产品[180] - 公司正在进行三项自主研发的UCART产品候选药物的临床试验[182,183,184,185] - 公司与Servier和Allogene公司就抗CD19项目进行合作[186,187] - 公司与Allogene公司就抗BCMA和抗CD70项目进行合作[188] 财务表现 - 公司收入增加12.3百万美元，主要来自于2024年上半年确认的6.8百万美元AZ JRCA第一个研究计划的履约收入以及5.4百万美元的Servier里程碑收入[200] - 研发费用增加2.2百万美元，主要是制造活动支持管线研发的外部费用增加3.1百万美元[204] - 销售及管理费用基本持平，增加0.1百万美元[205,206,207] - 净财务收益增加28.3百万美元，主要来自于金融投资收益增加3.2百万美元、SIA衍生工具公允价值变动收益14.3百万美元、EIB认股权公允价值变动收益4.3百万美元[211,212] - 净亏损从2023年上半年的49.2百万美元减少到2024年上半年的19.6百万美元，主要得益于收入和其他收益增加10.4百万美元、股份支付费用减少1.5百万美元、净财务收益增加28.3百万美元以及其他营业外收支改善0.8百万美元[217] 公司管理及重大事项 - 公司任命Marc Dunoyer和Tyrell Rivers为董事[194] - 公司任命Arthur Stril为临时首席财务官[194] - 公司与Servier就许可协议纠纷启动仲裁程序[195] - 截至2024年6月30日,公司未发生其他重大事项[196] - 公司正在进行仲裁程序,如果裁决结果不利可能会对业务产生负面影响[230] 现金流及财务状况 - 公司与AstraZeneca公司签署联合研究合作协议并获得1000万美元里程碑付款[191] - 公司完成AstraZeneca公司140万美元的额外股权投资[192,193] - 公司截至2024年6月30日的现金及现金等价物为1.49亿美元，定期存款为1.19亿美元[221] - 2024年上半年经营活动产生的净现金流入为2,886.5万美元，主要来自许可和合作协议的现金流入1,370万美元、增值税退税160万美元、金融投资收益460万美元[223] - 2024年上半年投资活动产生的净现金流出为10,848万美元，主要用于增加1.062亿美元的流动性金融资产[225] - 2024年上半年筹资活动产生的净现金流入为9,040.6万美元，主要包括来自AstraZeneca的1.4亿美元资本增资和来自欧洲投资银行的1,620万美元贷款[225] - 公司预计目前的现金及存款足以支持运营至2026年[227]

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provid ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Cellectis' CLLS52 (alemtuzumab), an Investigational Medicinal Product (IMP) used as part of the lymphodepletion regimen associated with UCART22, evaluated in th ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Cellectis’ CLLS52 (alemtuzumab), an Investigational Medicinal Product (IMP) used as part of the lymphodepletion regimen associated with UCART22, evaluated in th ...

文章核心观点 - 急性淋巴细胞白血病(ALL)占美国白血病病例的10%,进展迅速,如果不治疗通常在几周或几个月内死亡 [1][3] - 对于不适合接受造血干细胞移植或在CD19靶向CAR T细胞治疗和/或造血干细胞移植后复发的ALL患者,迫切需要开发新的治疗方法 [4] - 美国FDA授予UCART22孤儿药物和罕见儿童疾病指定地位,这是开发可随时供所有患者使用的异基因CAR T产品的重要一步 [2][4] 公司概况 - Cellectis是一家临床阶段生物技术公司,利用其开创性的基因编辑平台开发拯救生命的细胞和基因疗法 [8] - Cellectis采用异基因方法进行CAR-T免疫治疗,开创了现成和随时可用的基因编辑CAR T细胞治疗癌症患者的概念 [8] - Cellectis拥有24年以上的基因编辑经验和专业知识,正在利用TALEN基因编辑技术和PulseAgile电穿孔系统开发改变生命的产品候选药物 [8] UCART22项目进展 - UCART22是一种针对CD22的异基因CAR T细胞产品候选药物,正在BALLI-01 I/II期临床试验中评估 [5] - 2023年12月在美国血液学会上公布的最新临床数据显示,UCART22-P2(由Cellectis完全制造)的疗效更佳,Dose Level 2的初步反应率为67%,优于Dose Level 3的UCART22-P1(由外部CDMO制造)的50%反应率 [6] - Cellectis预计将在2024年底前提供BALLI-01试验进展的更新信息 [6] 监管进展 - FDA授予UCART22孤儿药物和罕见儿童疾病指定地位,这可能有助于加快开发、批准和商业化治疗药物的进程,并有机会获得罕见儿童疾病优先审评券 [7]

Cellectis S.A. (CLLS) has been beaten down lately with too much selling pressure. While the stock has lost 22.8% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator ...